|
1
|
Insalaco L, Di Gaudio F, Terrasi M, Amodeo
V, Caruso S, Corsini LR, Fanale D, Margarese N, Santini D, Bazan V
and Russo A: Analysis of molecular mechanisms and anti-tumoural
effects of zoledronic acid in breast cancer cells. J Cell Mol Med.
16:2186–2195. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Soki FN, Li X, Berry J, Koh A, Sinder BP,
Qian X, Kozloff KM, Taichman RS and McCauley LK: The effects of
zoledronic acid in the bone and vasculature support of
hematopoietic stem cell niches. J Cell Biochem. 114:67–78. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Murphy CM, Schindeler A, Gleeson JP, Yu
NY, Cantrill LC, Mikulec K, Peacock L, O'Brien FJ and Little DG: A
collagen-hydroxyapatite scaffold allows for binding and co-delivery
of recombinant bone morphogenetic proteins and bisphosphonates.
Acta Biomater. 10:2250–2258. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brennan MA, Gleeson JP, O'Brien FJ and
McNamara LM: Effects of ageing, prolonged estrogen deficiency and
zoledronate on bone tissue mineral distribution. J Mech Behav
Biomed Mater. 29:161–170. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Voskaridou E, Christoulas D, Plata E,
Bratengeier C, Anastasilakis AD, Komninaka V, Kaliontzi D,
Gkotzamanidou M, Polyzos SA, Dimopoulou M and Terpos E: High
circulating sclerostin is present in patients with
thalassemia-associated osteoporosis and correlates with bone
mineral density. Horm Metab Res. 44:909–913. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Das S, Edwards PA, Crockett JC and Rogers
MJ: Upregulation of endogenous farnesyl diphosphate synthase
overcomes the inhibitory effect of bisphosphonate on protein
prenylation in Hela cells. Biochim Biophys Acta. 1841:569–573.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dedes PG, Kanakis I, Gialeli Ch,
Theocharis AD, Tsegenidis T, Kletsas D, Tzanakakis GN and Karamanos
NK: Preclinical evaluation of zoledronate using an in vitro mimetic
cellular model for breast cancer metastatic bone disease. Biochim
Biophys Acta. 1830:3625–3634. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Evdokiou A, Labrinidis A, Bouralexis S,
Hay S and Findlay DM: Induction of cell death of human osteogenic
sarcoma cells by zoledronic acid resembles anoikis. Bone.
33:216–228. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Majithia N, Atherton PJ, Lafky JM,
Wagner-Johnston N, Olson J, Dakhil SR, Perez EA, Loprinzi CL and
Hines SL: Zoledronic acid for treatment of osteopenia and
osteoporosis in women with primary breast cancer undergoing
adjuvant aromatase inhibitor therapy: A 5-year follow-up. Support
Care Cancer. 24:1219–1226. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tada Y, Hiroshima K, Shimada H, Shingyoji
M, Suzuki T, Umezawa H, Sekine I, Takiguchi Y, Tatsumi K and Tagawa
M: An intrapleural administration of zoledronic acid for inoperable
malignant mesothelioma patients: A phase I clinical study protocol.
Springerplus. 5:1952016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kroep JR, Charehbili A, Coleman RE, Aft
RL, Hasegawa Y, Winter MC, Weilbaecher K, Akazawa K, Hinsley S,
Putter H, et al: Effects of neoadjuvant chemotherapy with or
without zoledronic acid on pathological response: A meta-analysis
of randomized trials. Eur J Cancer. 54:57–63. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
James ND, Sydes MR, Clarke NW, Mason MD,
Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard
G, et al: Addition of docetaxel, zoledronic acid, or both to
first-line long-term hormone therapy in prostate cancer (stampede):
Survival results from an adaptive, multiarm, multistage, platform
randomised controlled trial. Lancet. 387:1163–1177. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kellinsalmi M, Mönkkönen H, Mönkkönen J,
Leskelä HV, Parikka V, Hämäläinen M and Lehenkari P: In vitro
comparison of clodronate, pamidronate and zoledronic acid effects
on rat osteoclasts and human stem cell-derived osteoblasts. Basic
Clin Pharmacol Toxicol. 97:382–391. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Russell RG, Xia Z, Dunford JE, Oppermann
U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps
RJ, et al: Bisphosphonates: An update on mechanisms of action and
how these relate to clinical efficacy. Ann N Y Acad Sci.
1117:209–257. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Little DG, Peacock L, Mikulec K, Kneissel
M, Kramer I, Cheng TL, Schindeler A and Munns C: Combination
sclerostin antibody and zoledronic acid treatment outperforms
either treatment alone in a mouse model of osteogenesis imperfecta.
Bone. 101:96–103. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Raje N, Terpos E, Willenbacher W, Shimizu
K, García-Sanz R, Durie B, Legieć W, Krejčí M, Laribi K, Zhu L, et
al: Denosumab versus zoledronic acid in bone disease treatment of
newly diagnosed multiple myeloma: An international, double-blind,
double-dummy, randomised, controlled, phase 3 study. Lancet Oncol.
19:370–381. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Byun JH, Jang S, Lee S, Park S, Yoon HK,
Yoon BH and Ha YC: The efficacy of bisphosphonates for prevention
of osteoporotic fracture: An update meta-analysis. J Bone Metab.
24:37–49. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Di Bari JA, Nead JA and Schurman SJ:
Zoledronic acid for neonatal subcutaneous fat necrosis. Clin Case
Rep. 5:567–569. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mayilvaganan S, Sarathi Vijaya HA and
Shivaprasad C: Preoperative zoledronic acid therapy prevent hungry
bone syndrome in patients with primary hyperparathyroidism. Indian
J Endocrinol Metab. 21:76–79. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hayer PS, Deane AK, Agrawal A, Maheshwari
R and Juyal A: Effect of zoledronic acid on fracture healing in
osteoporotic patients with intertrochanteric fractures. Int J Appl
Basic Med Res. 7:48–52. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Anastasilakis AD, Polyzos SA, Gkiomisi A,
Saridakis ZG, Digkas D, Bisbinas I, Sakellariou GT, Papatheodorou
A, Kokkoris P and Makras P: Denosumab versus zoledronic acid in
patients previously treated with zoledronic acid. Osteoporos Int.
26:2521–2527. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hattori Y, Yamashita J, Sakaida C, Kawano
K and Yonemochi E: Evaluation of antitumor effect of zoledronic
acid entrapped in folate-linked liposome for targeting to
tumor-associated macrophages. J Liposome Res. 25:131–140. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lézot F, Chesneau J, Navet B, Gobin B,
Amiaud J, Choi Y, Yagita H, Castaneda B, Berdal A, Mueller CG, et
al: Skeletal consequences of RANKL-blocking antibody (IK22-5)
injections during growth: Mouse strain disparities and synergic
effect with zoledronic acid. Bone. 73:51–59. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ishizuna K, Ota D, Fukuuchi A, Teraoka M,
Fujii A, Mori M and Nishi T: A case of femoral diaphyseal fracture
after long-term treatment with zoledronic acid. Breast Cancer.
22:90–94. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen KH, Wu PK, Chen CF and Chen WM:
Zoledronic acid-loaded bone cement as a local adjuvant therapy for
giant cell tumor of the sacrum after intralesional curettage. Eur
Spine J. 24:2182–2188. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hattori Y, Shibuya K, Kojima K, Miatmoko
A, Kawano K, Ozaki K and Yonemochi E: Zoledronic acid enhances
antitumor efficacy of liposomal doxorubicin. Int J Oncol.
47:211–219. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tisdale JE, Allen MR, Overholser BR,
Jaynes HA and Kovacs RJ: Influence of zoledronic acid on atrial
electrophysiological parameters and electrocardiographic
measurements. J Cardiovasc Electrophysiol. 26:671–677. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Luo KW, Ko CH, Yue GG, Gao S, Lee JK, Li
G, Fung KP, Leung PC, Evdokiou A and Lau CB: The combined use of
Camellia sinensis and metronomic zoledronic acid in a breast
cancer-induced osteolysis mouse model. J Cancer Res Clin Oncol.
141:1025–1036. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Martin CK, Dirksen WP, Carlton MM, Lanigan
LG, Pillai SP, Werbeck JL, Simmons JK, Hildreth BE III, London CA,
Toribio RE and Rosol TJ: Combined zoledronic acid and meloxicam
reduced bone loss and tumour growth in an orthotopic mouse model of
bone-invasive oral squamous cell carcinoma. Vet Comp Oncol.
13:203–217. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Günaldi M, Afsar CU, Duman BB, Kara IO,
Tatli U and Sahin B: Effect of the cumulative dose of zoledronic
acid on the pathogenesis of osteonecrosis of the jaws. Oncol Lett.
10:439–442. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hiroshima Y, Maawy AA, Katz MH, Fleming
JB, Bouvet M, Endo I and Hoffman RM: Selective efficacy of
zoledronic acid on metastasis in a patient-derived orthotopic
xenograph (PDOX) nude-mouse model of human pancreatic cancer. J
Surg Oncol. 111:311–315. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Luedders DW, Steinhoff J, Thill M, Rody A
and Bohlmann MK: Lack of difference in acute nephrotoxicity of
intravenous bisphosphonates zoledronic acid and ibandronate in
women with breast cancer and bone metastases. Anticancer Res.
35:1797–1802. 2015.PubMed/NCBI
|
|
33
|
Wu D, Ma J, Bao S and Guan H: Continuous
effect with long-term safety in zoledronic acid therapy for
polyostotic fibrous dysplasia with severe bone destruction.
Rheumatol Int. 35:767–772. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mönkkönen H, Ottewell PD, Kuokkanen J,
Mönkkönen J, Auriola S and Holen I: Zoledronic acid-induced
IPP/ApppI production in vivo. Life Sci. 81:1066–1070. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tanaka Y, Nagai Y, Dohdoh M, Oizumi T,
Ohki A, Kuroishi T, Sugawara S and Endo Y: In vitro cytotoxicity of
zoledronate (nitrogen-containing bisphosphonate: NBP) and/or
etidronate (non-NBP) in tumour cells and periodontal cells. Arch
Oral Biol. 58:628–637. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kimachi K, Kajiya H, Nakayama S, Ikebe T
and Okabe K: Zoledronic acid inhibits RANK expression and migration
of osteoclast precursors during osteoclastogenesis. Naunyn
Schmiedebergs Arch Pharmacol. 383:297–308. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Denoyelle C, Hong L, Vannier JP, Soria J
and Soria C: New insights into the actions of bisphosphonate
zoledronic acid in breast cancer cells by dual RhoA-dependent and
-independent effects. Br J Cancer. 88:1631–1640. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhou Z, Guan H, Duan X and Kleinerman ES:
Zoledronic acid inhibits primary bone tumor growth in Ewing
sarcoma. Cancer. 104:1713–1720. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen T, Berenson J, Vescio R, Swift R,
Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, et al:
Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer
patients with bone metastases. J Clin Pharmacol. 42:1228–1236.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zara S, De Colli M, di Giacomo V, Zizzari
VL, Di Nisio C, Di Tore U, Salini V, Gallorini M, Tetè S and
Cataldi A: Zoledronic acid at subtoxic dose extends osteoblastic
stage span of primary human osteoblasts. Clin Oral Investig.
19:601–611. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gnant M, Mlineritsch B, Stoeger H,
Luschin-Ebengreuth G, Knauer M, Moik M, Jakesz R, Seifert M,
Taucher S, Bjelic-Radisic V, et al: Zoledronic acid combined with
adjuvant endocrine therapy of tamoxifen versus anastrozol plus
ovarian function suppression in premenopausal early breast cancer:
Final analysis of the Austrian Breast and Colorectal Cancer Study
Group Trial 12. Ann Oncol. 26:313–320. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chien MC, Mascarenhas L, Hammoudeh JA and
Venkatramani R: Zoledronic acid for the treatment of children with
refractory central giant cell granuloma. J Pediatr Hematol Oncol.
37:e399–e401. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yang Y, Luo X, Yan F, Jiang Z, Li Y, Fang
C and Shen J: Effect of zoledronic acid on vertebral marrow
adiposity in postmenopausal osteoporosis assessed by MR
spectroscopy. Skeletal Radiol. 44:1499–1505. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Honda Y, Takahashi S, Zhang Y, Ono A,
Murakami E, Shi N, Kawaoka T, Miki D, Tsuge M, Hiraga N, et al:
Effects of bisphosphonate zoledronic acid in hepatocellular
carcinoma, depending on mevalonate pathway. J Gastroenterol
Hepatol. 30:619–627. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kalder M, Kyvernitakis I, Albert US,
Baier-Ebert M and Hadji P: Effects of zoledronic acid versus
placebo on bone mineral density and bone texture analysis assessed
by the trabecular bone score in premenopausal women with breast
cancer treatment-induced bone loss: Results of the ProBONE II
substudy. Osteoporos Int. 26:353–360. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Himelstein AL, Foster JC, Khatcheressian
JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS,
O'Connor T, et al: Effect of longer-interval vs standard dosing of
zoledronic acid on skeletal events in patients with bone
metastases: A randomized clinical trial. JAMA. 317:48–58. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Scheper MA, Badros A, Salama AR, Warburton
G, Cullen KJ, Weikel DS and Meiller TF: A novel bioassay model to
determine clinically significant bisphosphonate levels. Support
Care Cancer. 17:1553–1557. 2009. View Article : Google Scholar : PubMed/NCBI
|
